Ann: Opthea to Present at Clinical Trials at the Summit Meeting, page-5

I purchased last year below 35, then sold out at 69.5 and repurchased at an average of 61. I pegged you as a finance guy, not a biomed, so I'm interested to hear that you are a holder with a buy sentiment.

It is clear that OPT will need funding to take it through to the top line readout in Q2-Q3 2025, so discussing a capital raising or dilution isn't from my opinion self-defeating—it's recognizing what must happen. Do you see it differently?

It might be considered smart to wait on the sidelines, risk-free, until the funding needed to take OPT to the top line readout in Q3 2025 is secured before buying in. Despite this, on balance decided last year to not sit on the sidelines and instead built a holding. I intend to trim holding if or when OPT gets the me-too speculators jump in.